|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RBMX |
Gene summary for RBMX |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RBMX | Gene ID | 27316 |
| Gene name | RNA binding motif protein X-linked | |
| Gene Alias | HNRNPG | |
| Cytomap | Xq26.3 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | P38159 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 27316 | RBMX | GSM4909280 | Human | Breast | Precancer | 3.41e-02 | -5.06e-01 | 0.0305 |
| 27316 | RBMX | GSM4909286 | Human | Breast | IDC | 9.64e-11 | -2.22e-01 | 0.1081 |
| 27316 | RBMX | GSM4909288 | Human | Breast | IDC | 1.60e-03 | -4.46e-01 | 0.0988 |
| 27316 | RBMX | GSM4909290 | Human | Breast | IDC | 9.18e-05 | -3.41e-01 | 0.2096 |
| 27316 | RBMX | GSM4909294 | Human | Breast | IDC | 1.24e-10 | -4.23e-01 | 0.2022 |
| 27316 | RBMX | GSM4909296 | Human | Breast | IDC | 3.27e-23 | -5.68e-01 | 0.1524 |
| 27316 | RBMX | GSM4909297 | Human | Breast | IDC | 1.45e-17 | -3.35e-01 | 0.1517 |
| 27316 | RBMX | GSM4909301 | Human | Breast | IDC | 9.55e-09 | -3.96e-01 | 0.1577 |
| 27316 | RBMX | GSM4909302 | Human | Breast | IDC | 4.73e-13 | -4.76e-01 | 0.1545 |
| 27316 | RBMX | GSM4909307 | Human | Breast | IDC | 8.15e-05 | -3.53e-01 | 0.1569 |
| 27316 | RBMX | GSM4909308 | Human | Breast | IDC | 1.79e-03 | -2.04e-01 | 0.158 |
| 27316 | RBMX | GSM4909309 | Human | Breast | IDC | 3.11e-10 | -4.50e-01 | 0.0483 |
| 27316 | RBMX | GSM4909311 | Human | Breast | IDC | 3.60e-45 | -1.89e-01 | 0.1534 |
| 27316 | RBMX | GSM4909312 | Human | Breast | IDC | 9.17e-09 | -1.85e-01 | 0.1552 |
| 27316 | RBMX | GSM4909313 | Human | Breast | IDC | 2.15e-04 | -2.75e-01 | 0.0391 |
| 27316 | RBMX | GSM4909315 | Human | Breast | IDC | 4.96e-12 | -4.79e-01 | 0.21 |
| 27316 | RBMX | GSM4909316 | Human | Breast | IDC | 2.11e-05 | -4.79e-01 | 0.21 |
| 27316 | RBMX | GSM4909319 | Human | Breast | IDC | 2.01e-55 | -4.08e-01 | 0.1563 |
| 27316 | RBMX | GSM4909320 | Human | Breast | IDC | 1.53e-07 | -3.07e-01 | 0.1575 |
| 27316 | RBMX | GSM4909321 | Human | Breast | IDC | 7.33e-21 | -3.94e-01 | 0.1559 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00083809 | Breast | Precancer | RNA splicing | 65/1080 | 434/18723 | 1.27e-12 | 2.53e-10 | 65 |
| GO:00434849 | Breast | Precancer | regulation of RNA splicing | 34/1080 | 148/18723 | 2.66e-12 | 4.75e-10 | 34 |
| GO:00003759 | Breast | Precancer | RNA splicing, via transesterification reactions | 52/1080 | 324/18723 | 1.74e-11 | 2.22e-09 | 52 |
| GO:00003779 | Breast | Precancer | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
| GO:00003989 | Breast | Precancer | mRNA splicing, via spliceosome | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
| GO:00480249 | Breast | Precancer | regulation of mRNA splicing, via spliceosome | 22/1080 | 101/18723 | 5.29e-08 | 3.18e-06 | 22 |
| GO:19033118 | Breast | Precancer | regulation of mRNA metabolic process | 38/1080 | 288/18723 | 1.63e-06 | 5.97e-05 | 38 |
| GO:00506848 | Breast | Precancer | regulation of mRNA processing | 23/1080 | 137/18723 | 3.49e-06 | 1.13e-04 | 23 |
| GO:00331199 | Breast | Precancer | negative regulation of RNA splicing | 9/1080 | 25/18723 | 6.03e-06 | 1.72e-04 | 9 |
| GO:00003808 | Breast | Precancer | alternative mRNA splicing, via spliceosome | 15/1080 | 77/18723 | 2.86e-05 | 6.37e-04 | 15 |
| GO:00003818 | Breast | Precancer | regulation of alternative mRNA splicing, via spliceosome | 13/1080 | 60/18723 | 2.98e-05 | 6.58e-04 | 13 |
| GO:19033129 | Breast | Precancer | negative regulation of mRNA metabolic process | 16/1080 | 92/18723 | 6.70e-05 | 1.35e-03 | 16 |
| GO:00331207 | Breast | Precancer | positive regulation of RNA splicing | 9/1080 | 37/18723 | 1.96e-04 | 3.10e-03 | 9 |
| GO:00016496 | Breast | Precancer | osteoblast differentiation | 27/1080 | 229/18723 | 3.35e-04 | 4.73e-03 | 27 |
| GO:00480255 | Breast | Precancer | negative regulation of mRNA splicing, via spliceosome | 6/1080 | 20/18723 | 6.99e-04 | 8.43e-03 | 6 |
| GO:00506865 | Breast | Precancer | negative regulation of mRNA processing | 6/1080 | 29/18723 | 5.49e-03 | 4.01e-02 | 6 |
| GO:00480266 | Breast | Precancer | positive regulation of mRNA splicing, via spliceosome | 5/1080 | 22/18723 | 7.32e-03 | 4.88e-02 | 5 |
| GO:00015036 | Breast | Precancer | ossification | 36/1080 | 408/18723 | 7.53e-03 | 4.98e-02 | 36 |
| GO:000838014 | Breast | IDC | RNA splicing | 73/1434 | 434/18723 | 1.27e-10 | 1.57e-08 | 73 |
| GO:004348414 | Breast | IDC | regulation of RNA splicing | 36/1434 | 148/18723 | 3.32e-10 | 3.77e-08 | 36 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa030408 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
| hsa0304013 | Breast | Precancer | Spliceosome | 39/684 | 217/8465 | 1.44e-06 | 2.27e-05 | 1.74e-05 | 39 |
| hsa0304023 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
| hsa0304033 | Breast | IDC | Spliceosome | 40/867 | 217/8465 | 1.53e-04 | 1.42e-03 | 1.06e-03 | 40 |
| hsa0304043 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
| hsa0304053 | Breast | DCIS | Spliceosome | 40/846 | 217/8465 | 8.97e-05 | 8.52e-04 | 6.28e-04 | 40 |
| hsa030409 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
| hsa0304014 | Endometrium | AEH | Spliceosome | 54/1197 | 217/8465 | 1.47e-05 | 1.65e-04 | 1.21e-04 | 54 |
| hsa0304024 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
| hsa0304034 | Endometrium | EEC | Spliceosome | 54/1237 | 217/8465 | 3.78e-05 | 3.88e-04 | 2.89e-04 | 54 |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304042 | Liver | Cyst | Spliceosome | 19/339 | 217/8465 | 1.10e-03 | 1.22e-02 | 1.00e-02 | 19 |
| hsa0304052 | Liver | Cyst | Spliceosome | 19/339 | 217/8465 | 1.10e-03 | 1.22e-02 | 1.00e-02 | 19 |
| hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RBMX | SNV | Missense_Mutation | novel | c.605G>A | p.Arg202His | p.R202H | P38159 | protein_coding | tolerated(0.16) | benign(0.125) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RBMX | SNV | Missense_Mutation | c.212N>C | p.Gly71Ala | p.G71A | P38159 | protein_coding | deleterious(0) | possibly_damaging(0.831) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
| RBMX | SNV | Missense_Mutation | c.644N>T | p.Ser215Phe | p.S215F | P38159 | protein_coding | tolerated(0.08) | probably_damaging(0.917) | TCGA-B6-A0IH-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| RBMX | SNV | Missense_Mutation | c.1124N>T | p.Gly375Val | p.G375V | P38159 | protein_coding | deleterious(0.01) | benign(0.29) | TCGA-B6-A0IJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RBMX | SNV | Missense_Mutation | c.934N>A | p.Asp312Asn | p.D312N | P38159 | protein_coding | tolerated(0.07) | possibly_damaging(0.69) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RBMX | SNV | Missense_Mutation | novel | c.514N>A | p.Arg172Ser | p.R172S | P38159 | protein_coding | deleterious(0.04) | benign(0.345) | TCGA-E2-A1LL-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | docetaxel | PD |
| RBMX | SNV | Missense_Mutation | novel | c.845G>C | p.Arg282Thr | p.R282T | P38159 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RBMX | SNV | Missense_Mutation | novel | c.950N>A | p.Arg317His | p.R317H | P38159 | protein_coding | tolerated(0.15) | possibly_damaging(0.719) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| RBMX | SNV | Missense_Mutation | novel | c.66A>C | p.Lys22Asn | p.K22N | P38159 | protein_coding | deleterious(0.02) | benign(0.277) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| RBMX | SNV | Missense_Mutation | novel | c.1106N>A | p.Arg369His | p.R369H | P38159 | protein_coding | tolerated(0.54) | probably_damaging(0.964) | TCGA-AG-4008-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |